IL13RA2 and neoplasm: Here, we discuss several tumor antigens, such as interleukin-13 receptor subunit alpha 2 (IL-13Rα2) and epidermal growth factor receptor variant III (EGFRvIII), that have been targeted to develop CAR-T-cell therapies for GBM treatment.